Aplastic anemia: immunosuppressive therapy in 2010.

Area of Science:

• Hematology
• Immunology
• Internal Medicine

Background:

• Acquired aplastic anemia (AA) is a bone marrow failure syndrome with immune-mediated pathophysiology.
• Current standard immunosuppressive therapy (IST) for AA involves anti-thymocyte globulin (ATG) plus cyclosporine A (CyA).
• IST achieves response rates of 50-70% but frequent primary and secondary treatment failures persist.

Purpose of the Study:

• To review the current state of IST for AA in 2010.
• To explore strategies for improving current AA treatments.
• To discuss recent data on ATG preparation variability and its implications for AA care.

Main Methods:

• Literature review of the state of the art in IST for AA.
• Analysis of experimental and clinical data on AA pathophysiology.
• Discussion of recent findings regarding different ATG preparations.

Main Results:

• Standard IST (ATG + CyA) provides significant survival benefits but has limitations.
• Primary and secondary treatment failures after IST are common challenges in AA management.
• Emerging data suggest variability among different ATG preparations may impact treatment efficacy.

Conclusions:

• Improvements in IST are needed to address treatment failures in AA.
• The equality of different ATG preparations is questionable and warrants further investigation.
• Current standards of care for AA patients may require reconsideration based on ATG variability.